Patents by Inventor Marion Subklewe

Marion Subklewe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND LENALIDOMIDE
    Publication number: 20220275093
    Abstract: The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/WT1×CD3 bispecific antibody and lenalidomide.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian AUGSBERGER, Christian KLEIN, Sabine Marion SUBKLEWE
  • Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
    Patent number: 11229700
    Abstract: The present invention relates to a novel molecule comprising three binding sites with specificity for a tumor cell, for an effector cell and for a checkpoint molecule, respectively. Moreover, the present invention relates to a pharmaceutical composition comprising such a molecule and to uses of such a molecule.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: January 25, 2022
    Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
    Inventors: Karl-Peter Hopfner, Marion Subklewe, Nadine Magauer, Nadja Fenn
  • Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
    Patent number: 11053318
    Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 6, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Peter Kufer, Roman Kischel, Marion Subklewe, Christina Heitmueller
  • Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia
    Patent number: 10933132
    Abstract: The present invention provides a combination epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia, wherein the epigenetic factor is selected from the group consisting of histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) I inhibitors, hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibitors and ATRA (All Trans-retinoic acid). Accordingly, the invention provides a pharmaceutical composition comprising a CD33 targeting compound and at least one epigenetic factor and an epigenetic factor for use in the amelioration and/or treatment of a myeloid leukemia, wherein the epigenetic factor increases the responsiveness of a patient to a CD33 targeting compound.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: March 2, 2021
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Roland B. Walter, Marion Subklewe, Christina Krupka
  • ADMINISTRATION OF A BISPECIFIC CONSTRUCT BINDING TO CD33 AND CD3 FOR USE IN A METHOD FOR THE TREATMENT OF MYELOID LEUKEMIA
    Publication number: 20190127465
    Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
    Type: Application
    Filed: April 18, 2017
    Publication date: May 2, 2019
    Inventors: Gerhard Zugmaier, Peter Kufer, Roman Kischel, Marion Subklewe, Christina Krupka
  • TRISPECIFIC MOLECULE COMBINING SPECIFIC TUMOR TARGETING AND LOCAL IMMUNE CHECKPOINT INHIBITION
    Publication number: 20180311348
    Abstract: The present invention relates to a novel molecule comprising three binding sites with specificity for a tumor cell, for an effector cell and for a checkpoint molecule, respectively. Moreover, the present invention relates to a pharmaceutical composition comprising such a molecule and to uses of such a molecule.
    Type: Application
    Filed: November 9, 2016
    Publication date: November 1, 2018
    Inventors: Karl-Peter HOPFNER, Marion SUBKLEWE, Nadine MAGAUER, Nadja FENN
  • COMBINATION OF EPIGENETIC FACTORS AND BISPECIFIC COMPOUNDS TARGETING CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
    Publication number: 20160317657
    Abstract: The present invention provides a combination epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia, wherein the epigenetic factor is selected from the group consisting of histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) I inhibitors, hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibitors and ATRA (All Trans-retinoic acid). Accordingly, the invention provides a pharmaceutical composition comprising a CD33 targeting compound and at least one epigenetic factor and an epigenetic factor for use in the amelioration and/or treatment of a myeloid leukemia, wherein the epigenetic factor increases the responsiveness of a patient to a CD33 targeting compound.
    Type: Application
    Filed: September 15, 2014
    Publication date: November 3, 2016
    Inventors: Roland B. Walter, Marion Subklewe, Christina Krupka